These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 19243297)
1. Customizing the targeting of IGF-1 receptor. Baserga R Future Oncol; 2009 Feb; 5(1):43-50. PubMed ID: 19243297 [TBL] [Abstract][Full Text] [Related]
2. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Ozkan EE Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884 [TBL] [Abstract][Full Text] [Related]
3. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Hofmann F; García-Echeverría C Drug Discov Today; 2005 Aug; 10(15):1041-7. PubMed ID: 16055020 [TBL] [Abstract][Full Text] [Related]
4. The insulin receptor substrate-1: a biomarker for cancer? Baserga R Exp Cell Res; 2009 Mar; 315(5):727-32. PubMed ID: 18851963 [TBL] [Abstract][Full Text] [Related]
5. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208 [TBL] [Abstract][Full Text] [Related]
6. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904 [TBL] [Abstract][Full Text] [Related]
7. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627 [TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559 [TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Buck E; Mulvihill M Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886 [TBL] [Abstract][Full Text] [Related]
10. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Gualberto A; Pollak M Oncogene; 2009 Aug; 28(34):3009-21. PubMed ID: 19581933 [TBL] [Abstract][Full Text] [Related]
11. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811 [TBL] [Abstract][Full Text] [Related]
12. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I). Jernberg-Wiklund H; Nilsson K Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944 [TBL] [Abstract][Full Text] [Related]
13. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046 [TBL] [Abstract][Full Text] [Related]
14. Characterization of an antibody that can detect an activated IGF-I receptor in human cancers. Rubini M; D'Ambrosio C; Carturan S; Yumet G; Catalano E; Shan S; Huang Z; Criscuolo M; Pifferi M; Baserga R Exp Cell Res; 1999 Aug; 251(1):22-32. PubMed ID: 10438568 [TBL] [Abstract][Full Text] [Related]
16. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Chernicky CL; Yi L; Tan H; Gan SU; Ilan J Cancer Gene Ther; 2000 Mar; 7(3):384-95. PubMed ID: 10766344 [TBL] [Abstract][Full Text] [Related]
17. [Targeting insulin-like growth factors in the treatment of cancer]. Moro-Sibilot D; Coudurier M; Lantuejoul S Rev Mal Respir; 2010 Oct; 27(8):959-63. PubMed ID: 20965410 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies against components of the IGF system for cancer treatment. Feng Y; Dimitrov DS Curr Opin Drug Discov Devel; 2008 Mar; 11(2):178-85. PubMed ID: 18283605 [TBL] [Abstract][Full Text] [Related]
19. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Gualberto A; Pollak M Curr Drug Targets; 2009 Oct; 10(10):923-36. PubMed ID: 19663769 [TBL] [Abstract][Full Text] [Related]
20. IGF-IR: potential role in antitumor agents. Guerreiro AS; Boller D; Doepfner KT; Arcaro A Drug News Perspect; 2006 Jun; 19(5):261-72. PubMed ID: 16941048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]